Edwards Lifesciences' days of market dominance are numbered, and with Medtronic impending on its U.S. monopoly and Boston Scientific soon to enter the crowded European space, the California devicemaker is less than optimistic about 2014 sales.
Medtronic is touting stellar 7-year postmarketing patient results for one of its key artificial disc implants designed to treat degenerative spinal conditions. Researchers presented the data at a major conference--a shot of good news for the Minnesota company's struggling spinal division.
Notching another CE mark in its cardiac cache, Italian devicemaker Sorin nabbed European approval for its Intensia family of implantable cardiac defibrillator and cardiac resynchronization therapy devices.
Endoscopic device maker Xlumena has CE Mark approval in the EU for its AXIOS gastrointestinal stent and delivery system--but the endoscopic devices haven't yet cleared the FDA for sale in the U.S. To that end, the company has secured a fresh infusion of capital--$25 million.
HeartWare has bought out CircuLite for as much as $350 million, acquiring a cardiac assist device for less-severe patients and broadening its offerings in the heart failure world.
A stealthy Silicon Valley medical device firm has raised $3.8 million and may be aiming to do for neurovascular diseases what one of its founders helped do for high blood pressure.
Johnson & Johnson's $2.5 billion-plus agreement to settle as many as 8,000 lawsuits over faulty metal hip implants made by its subsidiary, DePuy, is already getting pushback. Patients complain their attorneys and the company itself gain more than they do from the deal, and if discontent rises, it could place the overall agreement at risk.
Boston Scientific won FDA approval for yet another next-generation drug-eluting coronary stent system and has immediately ramped up its marketing machine to pursue new sales.
France's Pixium Vision reeled in $20.3 million in new financing to help further development of the company's retinal implant system designed to help people with certain degenerative eye conditions see better.
C.R. Bard is gearing up for yet another lawsuit from a patient alleging injury from an unsafe vaginal mesh implant, but speculation remains that the company and at least some of its rivals will reach a massive, collective settlement in the coming weeks.